A groundbreaking study reveals that a single pill combining three hypertension medications at ultra-low doses is more effective and safer for newly diagnosed patients than traditional single-drug treatments.
On Wednesday, researchers from Gangbuk Samsung Hospital, led by Professor Seong Gi-cheol of the Cardiology Department, published their findings in the prestigious Journal of the American College of Cardiology (JACC).
Conventional hypertension treatment typically begins with a single medication, escalating the dosage or adding drugs if blood pressure remains uncontrolled.
This approach, however, increases the risk of side effects and often leads to poor medication adherence due to the burden of multiple pills.
To tackle these issues, Professor Seong’s team developed a combination pill containing one-third of the standard doses of three common antihypertensive drugs: amlodipine, losartan, and chlorthalidone.
The team conducted an 8-week trial across more than 20 South Korean hospitals, involving patients with mild to moderate hypertension (systolic blood pressure 140-180 mmHg).
Results showed that this ultra-low dose combination pill outperformed standard-dose losartan in blood pressure control and matched the efficacy of standard-dose amlodipine.
The new treatment also boasted an excellent safety profile, with serious side effects occurring in less than 1% of patients and no instances of common antihypertensive side effects like leg swelling.
This pioneering Phase III clinical study demonstrates that the ultra-low dose combination pill is not only more effective than standard monotherapy but also offers a superior safety profile, Professor Seong explained.
He added that by simplifying treatment regimens, it aims to improve patient compliance and streamline hypertension management for both healthcare providers and patients, potentially boosting stagnant hypertension control rates.
The pharmaceutical industry is also capitalizing on this trend, developing combination products to enhance medication adherence and capture a larger share of the hypertension treatment market.
Recent launches include low-dose triple combination pills and even quadruple combination therapies targeting both hypertension and dyslipidemia, addressing the growing number of patients with multiple cardiovascular risk factors.
